and pleuritic and joint symptoms. Proteinuria fell from 13 to 8 g in 24 hours, but immune complex levels rose again within hours of each session. CH50 fell, but later recovered. Free Clq did not appear. She relapsed after eight weeks, and two plasmaphereses were performed with FFP to increase serum complement. Immune complex levels now continued to fall for several days after exchange, with a substantial rise in CH50 and free C lq and a decrease in proteinuria to 2 5 g/24 hours. Eight more exchanges with FFP were used for the third relapse 10 weeks later. This produced a lasting rise in CH50, persisting free Clq, and normal levels of complexes. Her hypertension had been resistant to treatment and two months-later she died suddenly in hypertensive heart failure.
CASE 2
This 55-year-old housewife with systemic lupus erythematosus described 10 years of polyarthritis, severe malaise, Raynaud's syndrome, and facial rashes with photosensitivity. Simple anti-inflammatory agents and prednisolone 10 mg daily were not effective in relieving her joint symptoms.
Investigations Fistulation is a frequent complication of Crohn's disease, the reported incidence varying between 17 and 480%,1 2 small bowel fistulae outnumbering those from the large bowel by roughly 3 to 1. Most large bowel fistulae tend to reach the exterior via the vagina, the incidence of rectovaginal fistulae being 5 to 14 %.34 Rectouterine fistulation in Crohn's disease has not been described. severe vaginal discharge and recurrent labial abscesses, she agreed to an examination under anaesthetic, and a rectovaginal fistula was identified. She refused surgical excision of the rectum and was treated with oral prednisolone.
The patient was re-admitted to hospital as an emergency in August 1976 with a three-day history of malaise, rigors, suprapubic pain, and four months' amenorrhoea. Her temperature was 39 0 C and pulse rate 112/minute.
There was definite lower abdominal tenderness but no evidence of peritonitis. Investigations disclosed a haemoglobin of 9-7 g/dl and a white cell count of 16 x 109/1. Plain x-ray films of the abdomen showed a pelvic soft tissue mass and in the erect position a fluid level in what appeared to be a pelvic abscess. An examination under anaesthetic was performed before laparotomy, when a suprapubic mass was palpated, arising out of the pelvis. At operation this mass was found to be a large intrauterine abscess and there was no evidence of any other pelvic abscesses. There were extensive pelvic adhesions from the previous surgery. The abscess was drained by opening and marsupialising the fundus of the uterus, the edges being sutured to the lower end of the abdominal incision, and rapid symptomatic improvement followed. A gastrografin enema performed on the fifth postoperative day showed a long stricture in the pelvic colon with a fistulous communication between the upper rectum and the uterus (fig), the latter containing faeces. No rectovaginal fistula was demonstrated. A defunctioning transverse colostomy was performed five days later. After this procedure, the discharge from the uterine cavity gradually diminished and the drainage track closed within three weeks. There has been no overt reassertion of the uterine sepsis.
Discussion
The proxim-iity of the sigmoid colon and rectum to the vagina is generally held to be responsible for the high incidence of rectovaginal fistulae in colonic Crohn's disease. Probably the greater thickness of the uterine wall precludes the development of a rectouterine fistula. Nevertheless, colonic surgery had been performed twice in this patient-initially a sigmoid colectomy and later a colorectal anastomosis-and perhaps this was the predisposing factor in the development of the rectouterine fistula.
I Steinberg, D M, Cooke, W T, and Alexander-Williams, J, Gut, 1973, 14, 865. 2 Van Patter, et al, Gastroenterology, 1954, 26, 347. 3Lockhart-Mummery, H E, and Morson, B C, Gut, 1964 , 5, 493. 4 Korelitz, B I, Gut, 1967 , 8, 290. (Accepted 8 March 1977 University Surgical Unit, Sheffield Royal Infirmary C J STODDARD, FRCS, lecturer in surgery T T IRVIN, CHM, FRCS, consultant surgeon Post-traumatic reflex sympathetic dystrophy syndrome (Sudeck's atrophy): effects of regional guanethidine infusion and salmon calcitonin Patients with reflex sympathetic dystrophy syndrome (RSDS)' develop a localised high-turnover osteoporosis due to increased osteoclastic resorption, partly stimulated by immobilisation, and dependent on the presence of an intact thyroid and parathyroid. The affected hand is painful, swollen, and moves poorly, with trophic skin changes and vasomotor instability. Calcitonin may relieve bone pain and reduce increased osteoclastic activity in patients with Paget's disease of bone.2 Guanethidine has been used to produce local sympathetic blockade in many conditions.:' As RSDS comprises increased osteoclastic activity and sympathetic dysfunction, we investigated both calcitonin treatment and guanethidine blockade in a patient with post-traumatic RSDS (Sudeck's atrophy).
Case report
A 35-year-old lorry driver had his left hand crushed in December 1975. There were no fractures. After an initial period of recovery, the hand became increasingly painful and swollen. When seen in April 1976, his hand was immobile and swollen, and the skin was white with blue mottling. There was excessive palmar sweating and tenderness of the metacarpophalangeal and proximal interphalangeal joints. The fingers were held in flexion and could only bend a few degrees. The clinical diagnosis of RSDS was confirmed by the radiographic appearances of widespread patchy osteoporosis. He had physiotherapy but did not improve, and was therefore started on salmon calcitonin treatment (Calsynar; Armour Pharmaceutical Co Ltd), 50 MRCU twice daily. Before the first injection a bone scan was performed using Tc-labelled ethaine hydroxydiphosphonate (EHDP), which showed an increased uptake in the affected hand.
The calcitonin produced an immediate reduction in the serum calcium concentration of blood taken from the left forearm. No fall in serum calcium was observed in blood taken simultaneously from the right side (figure). Samples were obtained simultaneously from catheters in left and right median cubital veins. Serum calcium was measured by atomic absorption spectrophotometry.
Conversion: SI to traditional units-Calcium 1 mmol/lz 4 mg/100 ml.
After one month's treatment no clinical improvement was observed, although there was a considerable reduction in the uptake of EHDP in the affected left hand. We then induced blockade with guanethidine, using the technique of Hannington-Kiff.3 Within 12 hours the hand was much less swollen, had returned to its normal colour, and the hand and metacarpophalangeal joints were mobile and pain-free. Nevertheless, the middle and ring fingers remained white, immobile, and painful; hence five weeks later the procedure was repeated using a more distal injection. This produced a considerable and lasting improvement in the colour, range of movement, and level of pain in the two affected fingers.
Comment
Regional intravenous infusions of guanethidine produced a striking clinical improvement in this patient. RSDS may be a reflex-arc phenomenon, the efferent pathway being postganglionic fibres that are blocked by guanethidine. This blockade is sustained and is more complete than surgical sympathectomy, which is usually disappointing in RSDS. The absence of symptomatic improvement during the administration of salmon calcitonin was disappointing, as excellent results have been reported in patients with RSDS4 with the use of pig calcitonin, which may account for the difference. Salmon calcitonin did produce an immediate reduction in bone resorption, however, shown by the fall in serum calcium in the blood taken from the affected limb.5 This confirms the presence of an increase in osteoclastic bone resorption in RSDS. Inhibition of bone resorption persisted during the administration of calcitonin, as shown by a quantitive reduction in the uptake of labelled EHDP in the second bone scan. Our observations suggest that guanethidine may be a valuable therapeutic agent in patients with established RSDS. In our experience,
